Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Levi Strauss & Co. (LEVI) vs Revvity Inc (RVTY) Price & Performance

Levi Strauss & Co.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Levi Strauss & Co. vs Revvity Inc — how do they compare? Levi Strauss & Co. trades at $24.19 (market cap $9.21B), while Revvity Inc trades at $110.43 (market cap $11.87B). The key difference: Revvity Inc is the larger of the two by market cap, and Levi Strauss & Co. pays the higher dividend (2.68%). Which is the better fit depends on your goals.

LEVIRVTY
Market Cap
$9.21B$11.87B
Sector
Consumer CyclicalTechnology
52-Week High
$24.99$117.75
52-Week Low
$17.92$82.26
Enterprise Value
$10.52B$14.36B
Dividend Yield
2.68%0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Levi Strauss & Co.

Levi Strauss (LEVI) trades at $24.03, down 1.35% over the past day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.28, exceeding expectations of $0.24, and raised its full-year outlook. Strong fundamentals include a 61.72% gross margin and 9.66% net income margin, supported by a digital strategy driving direct-to-consumer growth. Analyst consensus is overwhelmingly bullish with an 83.33% buy rating and a $28.00 price target, implying significant upside from current levels.

Outlook remains positive given earnings momentum and dividend increases, but risks include tariff pressures and foreign exchange volatility noted in recent reports. The stock's valuation at a P/E of 17.4 appears reasonable relative to profitability, though competitive and macroeconomic headwinds warrant monitoring for sustained growth.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.

Returns comparison

Trailing returns across standard periods

About Levi Strauss & Co.

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver

Read more on LEVI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY